US Stock MarketDetailed Quotes
VIRX Viracta Therapeutics
- 0.161
- +0.001+0.56%
Close Dec 31 16:00 ET
- 0.164
- +0.003+1.68%
Post 20:01 ET
6.39MMarket Cap-0.15P/E (TTM)
0.175High0.160Low1.59MVolume0.166Open0.160Pre Close261.92KTurnover5.53%Turnover RatioLossP/E (Static)39.74MShares1.31052wk High-0.97P/B4.62MFloat Cap0.13252wk Low--Dividend TTM28.69MShs Float9324.000Historical High--Div YieldTTM9.38%Amplitude0.132Historical Low0.165Avg Price1Lot Size
About Viracta Therapeutics Company
Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas. The company was founded on February 10, 1998 and is headquartered in Cardiff, CA.
Company Profile
SymbolVIRX
Company NameViracta Therapeutics
Listing DateSep 27, 2005
Issue Price7.00
Founded1998
CEOMr. Mark Andrew Rothera
MarketNASDAQ
Employees40
Fiscal Year Ends12-31
Address2533 South Coast Highway 101,Suite 210
CityCardiff
ProvinceCalifornia
CountryUnited States of America
Zip Code92007
Phone1-858-400-8470
Websitehttp://www.viracta.com
Company Executives
- Name
- Position
- Salary
- Mark Andrew Rothera
- Chief Executive Officer, President and Director
- 1.46M
- Michael E. Faerm
- Chief Financial Officer and Principal Accounting Officer
- --
- Dr. Darrel P. Cohen, M.D.,PhD
- Chief Medical Officer
- 756.73K
- Dr. Melody Burcar
- Senior Vice President, Finance
- --
- Dr. Roger J. Pomerantz, F.A.C.P.,M.D.
- Chairman of the Board
- 210.27K
- Dr. Ivor Royston, M.D.
- Director
- 90.76K
- Thomas E. Darcy
- Independent Director
- 113.26K
- Dr. Flavia Borellini, PhD
- Independent Director
- 92.36K
Heat List
US
Overall
Symbol
Price
% Chg
No Data